Weight-loss drug startup Metsera wants to take on Novo and Lilly. Here s what you need to know

Get the Full StoryWith 290 million in funding and a team of industry veterans, the new company hopes to enter a category of obesity treatments that has taken the country by storm.

Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a broad portfolio of weight-loss treatments that it hopes to bring to market.

Share: